Evidence map›Paper›PMID 38668786›Full record

ReviewJournal of molecular medicine (Berlin, Germany)2024

Mechanistic complement of autosomal dominant polycystic kidney disease: the role of aquaporins.

Qiumei Lan, Jie Li, Hanqing Zhang, Zijun Zhou, Yaxuan Fang, Bo Yang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of molecular medicine (Berlin, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Qiumei Lan *First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China.
Jie Li *First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China.
Hanqing ZhangFirst Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China.
Zijun ZhouFirst Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China.
Yaxuan FangFirst Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China.
Bo YangFirst Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China. yb8203@126.com.ORCID 0000-0002-2286-8156

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autosomal dominant polycystic kidney disease is a genetic kidney disease caused by mutations in the genes PKD1 or PKD2. Its course is characterized by the formation of progressively enlarged cysts in the renal tubules bilaterally. The basic genetic explanation for autosomal dominant polycystic kidney disease is the double-hit theory, and many of its mechanistic issues can be explained by the cilia doctrine. However, the precise molecular mechanisms underpinning this condition's occurrence are still not completely understood. Experimental evidence suggests that aquaporins, a class of transmembrane channel proteins, including aquaporin-1, aquaporin-2, aquaporin-3, and aquaporin-11, are involved in the mechanism of autosomal dominant polycystic kidney disease. Aquaporins are either a potential new target for the treatment of autosomal dominant polycystic kidney disease, and further study into the physiopathological role of aquaporins in autosomal dominant polycystic kidney disease will assist to clarify the disease's pathophysiology and increase the pool of potential treatment options. We primarily cover pertinent findings on aquaporins in autosomal dominant polycystic kidney disease in this review.

Indexed as

AquaporinsPolycystic Kidney, Autosomal DominantAnimalsHumansMutationAquaporinsADPKDAQPscAMPCyst

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.